Zealand Pharma A/S (OTCMKTS:ZLDPF) Hits New 12-Month Low – Here’s Why

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report)’s stock price reached a new 52-week low during mid-day trading on Thursday. The company traded as low as $31.63 and last traded at $31.63, with a volume of 200 shares trading hands. The stock had previously closed at $35.50.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on ZLDPF shares. Barclays downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 8th. Zacks Research cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 10th. Finally, Wells Fargo & Company reissued an “overweight” rating on shares of Zealand Pharma A/S in a research note on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold”.

View Our Latest Stock Analysis on Zealand Pharma A/S

Zealand Pharma A/S Stock Performance

The company has a debt-to-equity ratio of 0.02, a current ratio of 13.98 and a quick ratio of 13.98. The stock has a market cap of $2.27 billion, a price-to-earnings ratio of 4.67 and a beta of 0.99. The stock’s 50-day moving average is $37.72 and its 200 day moving average is $46.02.

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.57) by $1.45. Zealand Pharma A/S had a return on equity of 19.70% and a net margin of 67.13%. The company had revenue of $0.62 million for the quarter, compared to analyst estimates of $1.33 million. As a group, analysts predict that Zealand Pharma A/S will post 5.35 earnings per share for the current fiscal year.

About Zealand Pharma A/S

(Get Free Report)

Zealand Pharma A/S is a biotechnology company headquartered in Copenhagen, Denmark. Founded in 1998, it discovers and develops peptide-based medicines, with a focus on metabolic diseases and rare conditions. The company’s portfolio has included Zegalogue (dasiglucagon), an injectable treatment approved in the United States for severe hypoglycemia in people with diabetes. Zealand also develops investigational medicines for areas such as obesity, liver disease and rare gastrointestinal disorders, and works with pharmaceutical partners to advance and commercialize selected programs.

Featured Articles

Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.